Registry for individuals with T-cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry aims to create a comprehensive database to enhance the understanding of T-cell lymphoma and related conditions. By collecting information from participants, researchers will analyze data to identify patterns and improve treatment outcomes. The study involves optional blood and nail samples for further analysis. It focuses on various types of T-cell and NK-cell lymphomas, providing a platform for future research and clinical advancements.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent
* Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
* Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):

  * T-cell prolymphocytic leukemia
  * T-cell large granular lymphocytic leukemia
  * Chronic lymphoproliferative disorder of NK cells
  * Aggressive NK-cell leukemia
  * Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
  * Chronic active EBV infection of T- and NK-cell type, systemic form
  * Hydroa vacciniforme-like lymphoproliferative disorder
  * Adult T-cell leukemia/lymphoma
  * Extranodal NK/T-cell lymphoma, nasal type
  * Enteropathy-associated T-cell lymphoma
  * Monomorphic epitheliotropic intestinal T-cell lymphoma
  * Intestinal T-cell lymphoma, not otherwise specified (NOS)
  * Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
  * Hepatosplenic T-cell lymphoma
  * Subcutaneous panniculitis-like T-cell lymphoma
  * Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
  * Sézary syndrome
  * Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
  * Primary cutaneous Gamma-Delta T-cell lymphoma
  * Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
  * Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
  * Peripheral T-cell lymphoma, not otherwise specified
  * Angioimmunoblastic T-cell lymphoma
  * Follicular T-cell lymphoma
  * Nodal peripheral T-cell lymphoma with TFH phenotype
  * Anaplastic large cell lymphoma, ALK-positive
  * Anaplastic large cell lymphoma, ALK-negative
  * Breast-implant associated anaplastic large cell lymphoma.
* NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.

Exclusion Criteria:

* Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
* Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

Where it's running

• Memorial Sloan Kettering at Basking Ridge (All protocol activities)
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth (All protocol activities)
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester (All protocol activities)
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting
• Memorial Sloan Kettering Nassau (All protocol activities)
  Uniondale, New York, United States Recruiting

Study contacts

• Principal investigator: Steven Horwitz, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Steven Horwitz, MD
• Email: horwitzs@MSKCC.ORG
• Phone: 646-608-2680

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating DR-01 for treating specific types of lymphomas

  This study is testing a new treatment called DR-01 to see if it can safely help adults with certain types of lymphomas feel better and fight their cancer.

  Recruiting at 36 sites Phase 1/2 Dren Bio · Birmingham, Alabama and 36 other locations · NCT05475925

• Testing new treatments for peripheral T-cell lymphoma

  This study is testing whether adding new drugs, duvelisib or CC-486, to standard chemotherapy can help people with peripheral T-cell lymphoma achieve better treatment results.

  Recruiting at 84 sites Phase 2 Alliance for Clinical Trials in Oncology · Little Rock, Arkansas and 95 other locations · NCT04803201

• Testing a new treatment for relapsed T-cell non-Hodgkin lymphoma

  This study is testing a new treatment called ST-001 to see if it can help people with relapsed T-cell non-Hodgkin lymphoma feel better and have fewer side effects.

  Recruiting at 10 sites Phase 1 SciTech Development, Inc. · Scottsdale, Arizona and 9 other locations · NCT04234048

• Azacitidine and abatacept for relapsed or refractory T-cell lymphoma

  This study tests a combination of azacitidine and abatacept to see if it can shrink tumors in adults whose T-cell lymphoma has come back or not responded to treatment.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07388563

• Comparing soquelitinib to standard treatments for certain types of relapsed T-cell lymphoma

  This study is testing if a new pill called soquelitinib can work better than regular treatments for people with certain types of relapsed T-cell lymphoma.

  Recruiting at 37 sites Phase 3 Corvus Pharmaceuticals, Inc. · Duarte, California and 36 other locations · NCT06561048

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.